A Shared Path for Two Different Diseases
Imagine living with chronic joint pain and stiffness. You might have rheumatoid arthritis (RA), which often affects the hands and feet. Or you might have axial spondyloarthritis (axSpA), which targets the spine and pelvis. They are different conditions, but they can feel confusingly similar.
Now, new research suggests these diseases share more genetic roots than we knew. This could change how we understand and treat them.
Rheumatoid arthritis is an autoimmune disease where the body mistakenly attacks its own joints. It affects about 1% of adults worldwide. Axial spondyloarthritis is less common but still impacts millions, causing severe back pain and stiffness.
Current treatments often work by calming the immune system. But they don’t work for everyone. Doctors and patients often struggle with a long, frustrating journey to get the right diagnosis and treatment.
This study looks for common genetic threads. Finding them could help predict who gets sick and how to treat them better.
The Surprising Overlap
For years, RA and axSpA were seen as separate tracks. They have different symptoms and affect different joints. But doctors noticed some patients have features of both.
This study asked: Do they share genetic risk factors?
Researchers analyzed DNA from over 12,600 people with RA and 2,400 with axSpA. They compared them to more than 530,000 healthy people. They looked for tiny genetic differences, called SNPs, that are more common in people with these diseases.
They found 10 key SNPs that are linked to both conditions.
How Genes Can Act Like a Switch
Think of your genes as a set of instructions. A small change in the instructions—like a typo—can change how a protein is made. This can affect how your immune system works.
Some of these SNPs act like a stuck switch, turning on inflammation. Others act like a broken dial, turning it down too much.
The researchers didn’t just find the genes. They also checked what these genes do in the body. They measured levels of immune proteins and chemical messengers called cytokines.
This is a big step. It connects the genetic dots to real biological activity.
The Study at a Glance
This was a meta-analysis. That means scientists combined data from three large European studies: UK Biobank, FinnGen, and the REPAIR consortium. This gives the results more power and makes them more reliable.
They looked at thousands of people with RA or axSpA. They identified genetic variants and then used lab tests to see how those variants affected immune function.
The team found 10 independent SNPs linked to both diseases. Some increased risk, while others seemed protective.
For example, a variant in the HTT gene increased risk for both. But a variant in the CARMIL1 gene appeared to lower risk for both.
But here’s the twist: some genes acted differently in each disease.
A variant in the BTN2A1 gene was protective for RA but increased risk for axSpA. This shows how the same genetic change can have opposite effects in different diseases.
The researchers also linked these genes to specific immune signals. For instance:
- A GRM4 variant was tied to lower levels of CCL25, a chemical that guides immune cells.
- An ITPR3 variant was linked to reduced IL-10, a key anti-inflammatory signal.
- A ZNF322 variant affected TNFB and TGM2, proteins involved in immune signaling and tissue repair.
These findings help explain why these diseases develop and how they might be treated.
The Pattern Interrupt
This doesn’t mean we have a new treatment yet.
This study is a strong piece of the puzzle. It points to specific immune pathways that could be targeted with new drugs. For patients, it offers hope for more personalized medicine in the future.
If you have RA or axSpA, this research is promising but not immediately actionable. You cannot get a genetic test for these specific variants today to guide your care.
The best step is to talk with your doctor about your symptoms and treatment options. This study reinforces that these are complex diseases with deep biological roots.
This study has important limits. It only included people of European ancestry. The results may not apply to other populations. It also identifies associations, not direct causes. More research is needed to confirm these links and understand how they work.
Next, researchers will test these findings in larger, more diverse groups. They will also explore if targeting these genes or proteins can lead to new therapies. This work is still in the early stages, but it lays a foundation for future treatments.
